238 related articles for article (PubMed ID: 37226257)
1. Dual inhibition of IDO1/TDO2 enhances anti-tumor immunity in platinum-resistant non-small cell lung cancer.
Wu C; Spector SA; Theodoropoulos G; Nguyen DJM; Kim EY; Garcia A; Savaraj N; Lim DC; Paul A; Feun LG; Bickerdike M; Wangpaichitr M
Cancer Metab; 2023 May; 11(1):7. PubMed ID: 37226257
[TBL] [Abstract][Full Text] [Related]
2. Sodium Tanshinone IIA Sulfonate as a Potent IDO1/TDO2 Dual Inhibitor Enhances Anti-PD1 Therapy for Colorectal Cancer in Mice.
Zhang R; Wang Y; Liu D; Luo Q; Du P; Zhang H; Wu W
Front Pharmacol; 2022; 13():870848. PubMed ID: 35571116
[TBL] [Abstract][Full Text] [Related]
3. Targeting Tryptophan Catabolism in Ovarian Cancer to Attenuate Macrophage Infiltration and PD-L1 Expression.
Crump LS; Floyd JL; Kuo LW; Post MD; Bickerdike M; O'Neill K; Sompel K; Jordan KR; Corr BR; Marjon N; Woodruff ER; Richer JK; Bitler BG
Cancer Res Commun; 2024 Mar; 4(3):822-833. PubMed ID: 38451784
[TBL] [Abstract][Full Text] [Related]
4. Characterization of indoleamine-2,3-dioxygenase 1, tryptophan-2,3-dioxygenase, and Ido1/Tdo2 knockout mice.
Aslamkhan AG; Xu Q; Loughlin A; Vu H; Pacchione S; Bhatt B; Garfinkel I; Styring TG; LaFranco-Scheuch L; Pearson K; Reynolds S; Li N; Zhou H; Miller JR; Solban N; Bass A; Glaab WE
Toxicol Appl Pharmacol; 2020 Nov; 406():115216. PubMed ID: 32871117
[TBL] [Abstract][Full Text] [Related]
5. Targeting the Kynurenine Pathway for the Treatment of Cisplatin-Resistant Lung Cancer.
Nguyen DJM; Theodoropoulos G; Li YY; Wu C; Sha W; Feun LG; Lampidis TJ; Savaraj N; Wangpaichitr M
Mol Cancer Res; 2020 Jan; 18(1):105-117. PubMed ID: 31628200
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of Novel Inhibitors of Tryptophan Dioxygenases for Enzyme and Species Selectivity Using Engineered Tumour Cell Lines Expressing Either Murine or Human IDO1 or TDO2.
Tijono SM; Palmer BD; Tomek P; Flanagan JU; Henare K; Gamage S; Braun L; Ching LM
Pharmaceuticals (Basel); 2022 Aug; 15(9):. PubMed ID: 36145311
[TBL] [Abstract][Full Text] [Related]
7. Indoleamine 2,3-dioxygenase 1 inhibition targets anti-PD1-resistant lung tumors by blocking myeloid-derived suppressor cells.
Li A; Barsoumian HB; Schoenhals JE; Cushman TR; Caetano MS; Wang X; Valdecanas DR; Niknam S; Younes AI; Li G; Woodward WA; Cortez MA; Welsh JW
Cancer Lett; 2018 Sep; 431():54-63. PubMed ID: 29746927
[TBL] [Abstract][Full Text] [Related]
8. Targeting the IDO1/TDO2-KYN-AhR Pathway for Cancer Immunotherapy - Challenges and Opportunities.
Cheong JE; Sun L
Trends Pharmacol Sci; 2018 Mar; 39(3):307-325. PubMed ID: 29254698
[TBL] [Abstract][Full Text] [Related]
9. IL-1β mediates the induction of immune checkpoint regulators IDO1 and PD-L1 in lung adenocarcinoma cells.
Nawas AF; Solmonson A; Gao B; DeBerardinis RJ; Minna JD; Conacci-Sorrell M; Mendelson CR
Cell Commun Signal; 2023 Nov; 21(1):331. PubMed ID: 37985999
[TBL] [Abstract][Full Text] [Related]
10. Galectin 3 protects from cisplatin-induced acute kidney injury by promoting TLR-2-dependent activation of IDO1/Kynurenine pathway in renal DCs.
Volarevic V; Markovic BS; Jankovic MG; Djokovic B; Jovicic N; Harrell CR; Fellabaum C; Djonov V; Arsenijevic N; Lukic ML
Theranostics; 2019; 9(20):5976-6001. PubMed ID: 31534532
[TBL] [Abstract][Full Text] [Related]
11. Discovery and Characterisation of Dual Inhibitors of Tryptophan 2,3-Dioxygenase (TDO2) and Indoleamine 2,3-Dioxygenase 1 (IDO1) Using Virtual Screening.
Sari S; Tomek P; Leung E; Reynisson J
Molecules; 2019 Nov; 24(23):. PubMed ID: 31795096
[TBL] [Abstract][Full Text] [Related]
12. Preparation and evaluation of L- and D-5-[
Tang T; Gill HS; Ogasawara A; Tinianow JN; Vanderbilt AN; Williams SP; Hatzivassiliou G; White S; Sandoval W; DeMent K; Wong M; Marik J
Nucl Med Biol; 2017 Aug; 51():10-17. PubMed ID: 28511073
[TBL] [Abstract][Full Text] [Related]
13. IDO1 can impair NK cells function against non-small cell lung cancer by downregulation of NKG2D Ligand via ADAM10.
Fang X; Guo L; Xing Z; Shi L; Liang H; Li A; Kuang C; Tao B; Yang Q
Pharmacol Res; 2022 Mar; 177():106132. PubMed ID: 35183714
[TBL] [Abstract][Full Text] [Related]
14. Parallel discovery of selective and dual inhibitors of tryptophan dioxygenases IDO1 and TDO2 with a newly-modified enzymatic assay.
Capochiani de Iudicibus R; Tomek P; Palmer BD; Tijono SM; Flanagan JU; Ching LM
Bioorg Med Chem; 2021 Jun; 39():116160. PubMed ID: 33901770
[TBL] [Abstract][Full Text] [Related]
15. Peptide vaccination directed against IDO1-expressing immune cells elicits CD8
Dey S; Sutanto-Ward E; Kopp KL; DuHadaway J; Mondal A; Ghaban D; Lecoq I; Zocca MB; Merlo LMF; Mandik-Nayak L; Andersen MH; Pedersen AW; Muller AJ
J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32690770
[TBL] [Abstract][Full Text] [Related]
16. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
17. Non-tumor cell IDO1 predominantly contributes to enzyme activity and response to CTLA-4/PD-L1 inhibition in mouse glioblastoma.
Zhai L; Ladomersky E; Dostal CR; Lauing KL; Swoap K; Billingham LK; Gritsina G; Wu M; McCusker RH; Binder DC; Wainwright DA
Brain Behav Immun; 2017 May; 62():24-29. PubMed ID: 28179106
[TBL] [Abstract][Full Text] [Related]
18. Tobacco carcinogen induces tryptophan metabolism and immune suppression via induction of indoleamine 2,3-dioxygenase 1.
Liang F; Wang GZ; Wang Y; Yang YN; Wen ZS; Chen DN; Fang WF; Zhang B; Yang L; Zhang C; Han SC; Yang FY; Wang D; Liang LJ; Wang Z; Zhao Y; Wang CL; Zhang L; Zhou GB
Signal Transduct Target Ther; 2022 Sep; 7(1):311. PubMed ID: 36068203
[TBL] [Abstract][Full Text] [Related]
19. Tryptophan metabolism induced by TDO2 promotes prostatic cancer chemotherapy resistance in a AhR/c-Myc dependent manner.
Li F; Zhao Z; Zhang Z; Zhang Y; Guan W
BMC Cancer; 2021 Oct; 21(1):1112. PubMed ID: 34657603
[TBL] [Abstract][Full Text] [Related]
20. Carboxyamidotriazole combined with IDO1-Kyn-AhR pathway inhibitors profoundly enhances cancer immunotherapy.
Shi J; Chen C; Ju R; Wang Q; Li J; Guo L; Ye C; Zhang D
J Immunother Cancer; 2019 Sep; 7(1):246. PubMed ID: 31511064
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]